AI biotech Enveda secures $311M Series E funding at $2B valuation
The funding round was led by Catalio Capital Management, with participation from Iconiq and others, doubling Enveda's valuation from 12 months ago. The startup, founded in 2019, uses AI to discover new drugs from natural sources like plants and microbes. Enveda is currently testing several drugs in clinical trials, including treatments for severe skin conditions and a drug designed to help maintain weight loss after stopping GLP-1s.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
GRAM (Gram, prev. Toncoin) price pulls back to $1.057, hitting a nearly 365-day low
-
2
What is the LDN Token and How to Acquire and Trade It
-
3
BCH (Bitcoin Cash) trading volume reached $2.1 million over the past hour (15.2x its average for the same period over the past 7 days), currently trading at $247.900.
-
4
A Review of Major Global Blockchain Trading Platforms and Apps
-
5
ANKR Token Analysis: Current State and Future Outlook of Web3 Infrastructure
-
6
Real-World Use Cases and Impact of Blockchain Brawlers (BRWL)
-
7
2026 US Stock Market Safe-Haven Assets Encyclopedia: How Walmart and Caterpillar Lead the Industrial Sector Amid AI Bubble Doubts
-
8
What Cryptocurrency Is ADR? A Deep Dive into the Solana Meme Project American Dollar Reserve
-
9
How is BFHT doing? What is the future outlook for BFHT?
-
10
Current Status of BUSD (Binance USD): Issuance Halted, Orderly Wind-Down Underway
Markets Today
Recommended Reading






